clinical trial · NCT04345471
A Study of MD-120 in Patients With Depression
Mochida Pharmaceutical Company, Ltd.·phase3·completed·n = 615
Major Depressive DisorderDesvenlafaxine 100 mgDesvenlafaxine 50 mgPlacebo
brief summary
The purpose of this study is to verify the efficacy and evaluate the safety of 8-week once-daily oral administration of MD-120 in Japanese patients with depression.
started
May 18, 2020
primary completion
Jul 21, 2022
completion
Sep 14, 2022
last updated
Feb 29, 2024
official title
A Placebo-controlled Study of MD-120 in Patients With Depression
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol